AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31758329
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration (IV) of nafamostat mesilate (NM)
Trial: 26456487
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVT) - 3 monthly injections followed by PRN treatment
Trial: 20598985
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Valsartan and Captopril
Trial: 7782055
Drug: Follicle-stimulating hormone
RxNorm normalized name: Follicle-stimulating hormone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicle-stimulating hormone (FSH)
Trial: 3106101
Drug: Buserelin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (0.3 ml twice a day subcutaneously for 14 days) followed by FSH
Trial: 16984065
Drug: Empirical antisecretory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antisecretory therapy followed by Helicobacter pylori testing if symptoms improved
Trial: 16984065
Drug: Empirical antisecretory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antisecretory therapy
Trial: 1286496
Drug: Flumazenil (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.7 mg, 7 ml)
Trial: 1286496
Drug: Placebo (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (9 ml)
Trial: 27742871
Drug: Salbutamol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (400 µg)
Trial: 26922022
Drug: Ipratropium (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (80 µg)
Trial: 26922022
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (salbutamol and ipratropium)
Trial: 11241803
Drug: Indomethacin (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (i.v. 0.2 mg/kg b.w.)
Trial: 11241803
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (placebo, 20 mL)
Trial: 9647934
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy in hypogonadal men
Trial: 9647934
Drug: No testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No testosterone administration in eugonadal men
Trial: 12068251
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg ethanol
Trial: 31068229
Drug: Cream of
RxNorm normalized name: Nubasics Soup Cream of Chicken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream of Rice (CR)
Trial: 28454829
Drug: Culprit lesion
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culprit lesion treatment-only strategy
Trial: 24267005
Drug: Fortified milk
RxNorm normalized name: Fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified milk (100 IU vitamin D, 500 mg calcium per 200 mL)
Trial: 24267005
Drug: Fortified orange
RxNorm normalized name: Nutritional Supplement Oral Liquid [FORTIFIED ORANGE JUICE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified orange juice (100 IU vitamin D, 500 mg calcium per 200 mL)
Trial: 24267005
Drug: Supplement (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (200 IU vitamin D, 500 mg calcium)
Trial: 17954800
Drug: Chlorhexidine-based solution
RxNorm normalized name: chlorhexidine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-based solution (0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride, and 4% benzylic alcohol)
Trial: 1927943
Drug: Intermittent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent use of transdermal nitroglycerin (10 mg/24 hours)
Trial: 1927943
Drug: Continuous use
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous use of transdermal nitroglycerin (10 mg/24 hours)
Trial: 6356740
Drug: Gangliosides (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gangliosides (20 mg daily i.m.)
Trial: 29713850
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual
Trial: 30593607
Drug: MEDI4166 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4166 50 mg
Trial: 30593607
Drug: MEDI4166 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4166 200 mg
Trial: 30593607
Drug: MEDI4166 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4166 400 mg
Trial: 26808856
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg·kg body mass
Trial: 19699335
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day for 2 days
Trial: 2476978
Drug: Topical retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoic acid treatment
Trial: 26242578
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg daily)
Trial: 21658524
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (wait-list control)
Trial: 15329302
Drug: Neuropsychological assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropsychological assessment prior to smoking cessation treatment (including VSWM and WCST)
Trial: 11748103
Drug: Acetylcholine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine infusion in Hyperthyroidism (H)
Trial: 11748103
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion in Hyperthyroidism (H)
Trial: 9662077
Drug: Duodenal lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal lipid (Intralipid 20%) infusion for 45 minutes
Trial: 9662077
Drug: Duodenal lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal lipid (Intralipid 20%) infusion for 15 minutes
Trial: 20125186
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (CC)
Trial: 22155561
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 30 mg
Trial: 11570305
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy with low-dose acetylsalicylic acid (ASA) initiated within 48 hours of stroke onset
Trial: 8323207
Drug: Traditional graduated
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional graduated regimen of 30 ml/h for 24 h, 60 ml/h for 24 h, 90 ml/h for 24 h, then free fluids (group 2)
Trial: 25452452
Drug: Nivolumab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 0.3 mg/kg
Trial: 26861469
Drug: Nivolumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 2.0 mg/kg
Trial: 26861469
Drug: Nivolumab 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 10.0 mg/kg
Trial: 26861469
Drug: Nivolumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (all doses)
Trial: 22434968
Drug: Yoga exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga exercise for 50 minutes daily for 4 weeks
Trial: 15925132
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for body image concerns
Trial: 2030191
Drug: Preparation stage
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation stage
Trial: 7102445
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of stages
Trial: 19478198
Drug: Saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 2.5 mg plus metformin
Trial: 19478198
Drug: Saxagliptin (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (2.5, 5, and 10 mg) plus metformin
Trial: 24565221
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus metformin
Trial: 17192326
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy (infrared skin thermometer to measure temperatures on six foot sites daily)
Trial: 9725760
Drug: IV ASA
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ASA medication
Trial: 25354720
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid combined with androgen-deprivation therapy.
Trial: 24643488
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment intervention
Trial: 21983612
Drug: Toothpastes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpastes with natural compounds
Trial: 31142357
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy
Trial: 11384687
Drug: Vasopressin 10
RxNorm normalized name: VASOPRESSIN 10UNT/0.5ML INJ,VIL,0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin 10 units/10 mL of normal saline
Trial: 23188121
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg
Trial: 21939510
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid for two weeks
Trial: 24075764
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg/day
Trial: 18312764
Drug: fluvastatin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluvastatin XL 80 mg/day plus ezetimibe 10 mg/day
Trial: 16361021
Drug: Dexanabinol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexanabinol (150 mg intravenous dose within 6 hours of injury)
Trial: 12540407
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (subgroup >6 years postmenopause)
Trial: 8874308
Drug: Standard-dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose epinephrine (0.02 mg/kg)
Trial: 8874308
Drug: High-dose epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epinephrine (0.2 mg/kg)
Trial: 6430605
Drug: Mestranol 24
RxNorm normalized name: Mestranol
DrugBank: Mestranol (DB01357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mestranol 24 micrograms daily
Trial: 25268962
Drug: Current PPI
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current PPI use among patients receiving diuretics
Trial: 25268962
Drug: Current PPI
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current PPI use among patients not receiving diuretics
Trial: 25268962
Drug: Histamine H2
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H2 receptor antagonists
Trial: 16488958
Drug: Combined photodynamic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined photodynamic therapy (PDT) with intravitreal triamcinolone (IVTA)
Trial: 16488958
Drug: PDT monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT monotherapy
Trial: 15692919
Drug: Renal doses
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Renal doses of dopamine in the postoperative period
Trial: 15692919
Drug: Renal doses
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Renal doses of dopamine in the preoperative period
Trial: 7763202
Drug: Acetylcysteine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (50 mg/kg per day subcutaneously for 12 months)
Trial: 438014
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of dry air at various temperatures (subzero to 80 degrees C) during exercise
Trial: 438014
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of dry air at temperatures above 37 degrees C
Trial: 30554925
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine periarticular injection (PAI)
Trial: 3746543
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone (control group)
Trial: 25463545
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus albumin
Trial: 21327673
Drug: Propiverine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine ER 30 mg o.d. as add-on to α-blockers (CT)
Trial: 21327673
Drug: Propiverine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine ER 30 mg o.d. as monotherapy (MT)
Trial: 19617815
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) treatment with antiretroviral therapy (nucleoside analogues) for 12 months
Trial: 19617815
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy alone for 12 months
Trial: 19617815
Drug: IL-2 experienced
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 experienced adults on highly active antiretroviral therapy
Trial: 15740555
Drug: EC‐MPS 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 640 mg
Trial: 15740555
Drug: EC‐MPS 720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 720 mg
Trial: 15740555
Drug: MMF 1000
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 1000 mg
Trial: 10524663
Drug: Acetaminophen, aspirin,
RxNorm normalized name: Acetaminophen, Aspirin, and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, aspirin, and caffeine (AAC)
Trial: 1820903
Drug: New Levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Levothyroxine solution
Trial: 1820903
Drug: Reference L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference L-thyroxine solution
Trial: 3887851
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g daily)
Trial: 7042486
Drug: Caved-S (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caved-S (six tablets daily)
Trial: 12154424
Drug: Bronchial blocker
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchial blocker (BB) with single-lumen tube (SLT)
Trial: 7658498
Drug: Tamoxifen (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (specific dosage and duration not mentioned)
Trial: 10511361
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate
Trial: 26535958
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioral therapy (wCBT)
Trial: 7508828
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg
Trial: 9669812
Drug: Fluconazole in
RxNorm normalized name: fluconazole Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole in addition to standard prophylaxis (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Trial: 9669812
Drug: Standard prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylaxis only (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Trial: 27859599
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy (OIT)
Trial: 30447012
Drug: Online serious
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online serious game for dental treatment preparation
Trial: 19114188
Drug: Moderate-potassium adenosine-lidocaine
RxNorm normalized name: alum, potassium / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-potassium adenosine-lidocaine (MPAL) group (K(+), 10 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Trial: 19114188
Drug: High-potassium adenosine-lidocaine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-potassium adenosine-lidocaine (HPAL) group (K(+), 20 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Trial: 16543907
Drug: GW660511X 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW660511X 200 mg
Trial: 12941708
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg daily for 3 months)
Trial: 8653990
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg tablet)
Trial: 2903817
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg twice daily)
Trial: 6374681
Drug: Trazodone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone administered as divided doses twice daily
Trial: 6374681
Drug: Trazodone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone administered as a single dose at night
Trial: 6374681
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (single dose at night and divided doses)
Trial: 9731006
Drug: Theophylline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (mean serum level: 9.9 +/- 1.1 mg/L, Days 1 to 40) + inhaled salmeterol (50 microgram twice daily, Days 8 to 36)
Trial: 8067245
Drug: Oxymetazoline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline administered with a nasal bellows (OXBE)
Trial: 8067245
Drug: Oxymetazoline with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline with conventional nasal spray (OXSP)
Trial: 8067245
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (PLSP)
Trial: 27325390
Drug: G‐Pump glucagon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Pump glucagon 1.2 µg/kg
Trial: 27325390
Drug: GlucaGen 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GlucaGen 2.0 µg/kg
Trial: 27325390
Drug: G‐Pump glucagon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Pump glucagon
Trial: 24534400
Drug: Nebulized beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized beclomethasone 400 μg twice daily for 10 days
Trial: 24534400
Drug: Nebulized beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized beclomethasone 400 μg
Trial: 25943350
Drug: Postoperative docetaxel-5FU
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative docetaxel-5FU regimen (D 85 mg/m2, day 1 and 5FU 750 mg/m2/day continuous infusion, days 1-5 every 3 weeks) after preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) and locoregional treatment.
Trial: 25943350
Drug: Preoperative dose-intense
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) followed by mastectomy and radiotherapy.
Trial: 22266683
Drug: Footrot vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Footrot vaccine (Footvax, MSD) plus targeted antibiotic therapy (long‐acting amoxicillin, Betamox LA, Norbrook Pharmaceuticals)
Trial: 22266683
Drug: Targeted antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotic therapy only
Trial: 7630674
Drug: Prednisone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (2 mg/kg up to 60 mg)
Trial: 17049710
Drug: Biological threat
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological threat stimuli (CS-) not directed towards participants
Trial: 23748117
Drug: Naloxone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (8 mg)
Trial: 26340920
Drug: Alcohol group
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol group (0.7 g/kg)